Compare RZLT & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | EARN |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 200.3M |
| IPO Year | N/A | 2013 |
| Metric | RZLT | EARN |
|---|---|---|
| Price | $2.35 | $5.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $10.33 | $5.88 |
| AVG Volume (30 Days) | ★ 15.9M | 321.3K |
| Earning Date | 02-11-2026 | 02-20-2026 |
| Dividend Yield | N/A | ★ 18.01% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $35,893,000.00 |
| Revenue This Year | N/A | $8.43 |
| Revenue Next Year | N/A | $17.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.30 |
| 52 Week Low | $1.07 | $4.33 |
| 52 Week High | $11.46 | $6.82 |
| Indicator | RZLT | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 59.59 |
| Support Level | $1.87 | $5.23 |
| Resistance Level | $2.43 | $5.39 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 56.73 | 88.05 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.